Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

References

• NielsenJMKortewegTPolmanCHDiagnosingMSrecent guidelines and future goals focusing on magnetic resonance imagingInt MS J200714293417509251
   PubMedGoogle Scholar
• AminoffMJNervous system disordersMcPheeSJPapadakisMACurrent Medical Diagnosis and Treatment48th editionNew YorkMcGraw Hill Medical2009848911
   Google Scholar
• PoserCMBrinarVVThe accuracy of prevalence rates of multiple Sclerosis: a critical reviewNeuroepidemiology20072915015518042998
   PubMed Web of Science ®Google Scholar
• FoxCMBensaSBrayIZajicekJPThe epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteriaJ Neurol Neurosurg Psychiatry200475566014707308
   PubMed Web of Science ®Google Scholar
• Al-HashelJBestermanADWolfsonCThe prevalence of multiple sclerosis in the Middle EastNeuroepidemiology20083112913718716409
   PubMed Web of Science ®Google Scholar
• RiveraVMMultiple Sclerosis in Latin America, reality and challengeNeuroepidemiology20093229429519246934
   PubMed Web of Science ®Google Scholar
• WasayMKhatriIAKhealaniBSheeraniMMS in Asian countriesInt MS J200613586516696904
   PubMedGoogle Scholar
• García-GallegoAMorera-GuitartJPrevalence and characteristics of multiple sclerosis in the health district of the Marina AltaRev Neurol20023473273712080492
   PubMed Web of Science ®Google Scholar
• CeliusEGSmestadCChange in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decadesActa Neurol Scand Suppl2009189272919566494
   PubMedGoogle Scholar
• GoodinDSThe causal cascade to multiple sclerosis: a model for MS pathogenesisPLoS ONE20094112
   Web of Science ®Google Scholar
• KampmanMTBrustadMVitaminDA candidate for the environmental effect in multiple sclerosis – observations from NorwayNeuroepidemiology20083014014618382112
   PubMed Web of Science ®Google Scholar
• ChardDMillerDGrey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imagingJ Neurol Sci200928251119201002
   PubMed Web of Science ®Google Scholar
• VyshkinaTKalmanBAutoantibodies and neurodegeneration in multiple sclerosisLaboratory Investigation20088879680718521063
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSMoreauTAdeleinePRelapses and progression of disability in multiple sclerosisN Engl J Med20003431430143811078767
   PubMed Web of Science ®Google Scholar
• RichardsRGSampsonFCBeardSMTappendenPA review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic modelsHealth Technol Assess2002617312022938
   PubMedGoogle Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology198333144414526685237
   PubMed Web of Science ®Google Scholar
• WiendlHToykaKVRieckmannPGoldRHartungHPHohlfeldRMultiple Sclerosis Therapy Consensus Group (MSTCG)Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendationsJ Neurol20082551449146319005625
   PubMed Web of Science ®Google Scholar
• CristianoEArcegaRCorrealeJRecomendaciones para la optimización del tratamiento De la esclerosis múltiple en latinoaméricaRev Neurol20074449449817455164
   PubMed Web of Science ®Google Scholar
• ExtaviaSummary of Product CharacteristicsEuropean Medicines Agency20.052008 http://www.emea.europa.eu/humandocs/PDFs/EPAR/extavia/emea-combined-h933en.pdfAccessed Aug 12, 2009
   Google Scholar
• PaolicelliDDirenzoVTrojanoMReview of interferon beta-1b in the treatment of early and relapsing multiple sclerosisBiologics2009336937619707422
   PubMedGoogle Scholar
• ChiangJGloffCAYoshizawaCNWilliamsGJPharmacokinetics of recombinant interferon-beta ser in healthy volunteers and its effect on serum neopterinPharm Res1993105675728483840
   PubMed Web of Science ®Google Scholar
• RudickRADisease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeuticsArch Neurol1999561079108410488808
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group and the University of British Columbia. MS/MRI Analysis GroupInterferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trialNeurology199545127712857617182
   PubMed Web of Science ®Google Scholar
• TrojanoMPellegriniFFuianiANew natural history of interferon beta- treated relapsing multiple sclerosisAnn Neurol20076130030617444502
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHBENEFIT Study GroupEffect of early vs delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLancet2007370899717617276
   PubMed Web of Science ®Google Scholar
• European Study Group on Interferon beta-1b in secondary progressive MSPlacebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive MSLancet1998352149114979820296
   PubMed Web of Science ®Google Scholar
• GoodkinDEThe North American SP MS Study GroupInterferon beta-1b in secondary progressive MS: clinical and MRI results of a 3 year randomized controlled trial [abstract]Neurology2000542352
   Web of Science ®Google Scholar
• KhanOATselisACKamholzJAGarbernJYLewisRALisakRPA prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosisEur J Neurol2001814114811284992
   PubMed Web of Science ®Google Scholar
• KhanOATselisACKamholzJAGarbernJYLewisRALisakRPA prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing – remitting multiple sclerosis: results after 18 months of therapyMult Scler2001734935311795454
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol2009888989719729344
   PubMed Web of Science ®Google Scholar
• CadavidDWolanskyLJSkurnickJEfficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME studyNeurology2009721976198319279320
   PubMed Web of Science ®Google Scholar
• HurwitzBJJefferyDArnasonBTolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot studyClin Ther2008301102111218640466
   PubMed Web of Science ®Google Scholar
• GottesmanMHFriedman-UrevichSInterferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS)Mult Scler20061227128016764339
   PubMed Web of Science ®Google Scholar
• BanwellBRederATKruppLSafety and tolerability of interferon beta-1b in pediatric multiple sclerosisNeurology20066647247616505297
   PubMed Web of Science ®Google Scholar
• BurksJInterferon-beta 1b for multiple sclerosisExpert Rev Neurother2005515316415853486
   PubMedGoogle Scholar
• PolmanCKapposLWhiteREuropean Study Group in Interferon Beta-1b in Secondary Progressive MSNeutralizing antibodies during treatment of secondary progressive MS with interferon beta-1bNeurology200360374312525715
   PubMed Web of Science ®Google Scholar
• VerdunEIsoardoGOggeroABetaferon Safety Trial (BEST) Study GroupAutoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseasesJ Interferon Cytokine Res20022224525511911808
   PubMed Web of Science ®Google Scholar
• DurelliLFerreroBOggeroABetaferon Safety Trial (BEST) Study GroupLiver and thyroid function and autoimmunity during interferon- beta 1b treatment for MSNeurology2001571363137011673572
   PubMed Web of Science ®Google Scholar
• TworkSNippertISchererPHaasJPöhlauDKuglerJImmunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis populationCurr Med Res Opin2007231209121517559722
   PubMed Web of Science ®Google Scholar
• PortaccioEAmatoMPImproving compliance with interferon-beta therapy in patients with multiple sclerosisCNS Drugs20092345346219480465
   PubMed Web of Science ®Google Scholar
• GottbergKGardulfAFredriksonSInterferon-beta treatment for patients with multiple sclerosis: the patients’ perceptions of the side-effectsMult Scler2000634935411064446
   PubMed Web of Science ®Google Scholar
• MohrDCGoodkinDELikoskyWGattoNBaumannKARudickRATreatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosisArch Neurol1997545315339152109
   PubMed Web of Science ®Google Scholar
• BellCGrahamJEarnshawSOleen-BurkeyMCastelli-HaleyJJohnsonKCost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical dataJ Manag Care Pharm20071328728917407397
   PubMed Web of Science ®Google Scholar
• GoldbergLDEdwardsNCFincherCDoanQVAl-SabbaghAMeleticheDMComparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosisJ Manag Care Pharm20091554355519739877
   PubMed Web of Science ®Google Scholar
• KobeltGJönssonLFredriksonSCost-utility of interferon beta 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosisEur J Health Econ20034505915609169
   PubMedGoogle Scholar
• JankovićSMKostićMRadosavljevićMCost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socio-economic transitionVojnosanit Pregl20096655656219678581
   PubMed Web of Science ®Google Scholar
• GurtubayIGMoralesGGállegoJMartínEMaravíETolerance to interferon beta-1b amongst patients with remittent recurrent multiple sclerosis after more than one year of treatmentAn Sist Sanit Navar199821151912891417
   PubMedGoogle Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• SorensenPSRossCClemmesenKMDanish Multiple Sclerosis Study GroupClinical importance of neutralising antibodies against interferon beta in patients with relapsing remitting multiple sclerosisLancet20033621184119114568740
   PubMed Web of Science ®Google Scholar